Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

INDP - Indaptus Therapeutics, Inc. So'nggi... | Finranks

Home

INDP

I

Indaptus Therapeutics, Inc. (INDP)

NCM – Real vaqt narxi. Valyuta: USD

1.78

0.00 (0.00%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.81

+0.05 (3.13%)

Bozordan keyin: Mar 27, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus' Co-Chief Executive Officer and Chairman of the Board. Jeffrey Meckler will continue as Co-CEO and remain on the Board.

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that Michael Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 3rd Donor Selection & Cell Source Summit, taking place November 19–20, 2025, in San Diego, California.

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab.

Videolar

No Data

There is no data to display

Press-relizlar

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus' Co-Chief Executive Officer and Chairman of the Board. Jeffrey Meckler will continue as Co-CEO and remain on the Board.

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab.